[go: up one dir, main page]

US20130123212A1 - Anti-fatigue composition, formulation and use thereof - Google Patents

Anti-fatigue composition, formulation and use thereof Download PDF

Info

Publication number
US20130123212A1
US20130123212A1 US13/812,485 US201113812485A US2013123212A1 US 20130123212 A1 US20130123212 A1 US 20130123212A1 US 201113812485 A US201113812485 A US 201113812485A US 2013123212 A1 US2013123212 A1 US 2013123212A1
Authority
US
United States
Prior art keywords
protopanoxadiol
barbarum polysaccharide
lycium
fatigue
lycium barbarum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/812,485
Inventor
Changjiang Xu
Weiguo Jia
Chunying Yu
Wenjing Zhang
Qiyuan Han
Qiang Ge
Qinlin Wang
Zirong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE
Original Assignee
SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE filed Critical SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE
Assigned to SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE reassignment SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONAL CHINESE MEDICINE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GE, QIANG, HAN, QIYUAN, JIA, WEIGUO, WANG, QINLIN, YANG, ZIRONG, YU, CHUNYING, ZHANG, WENJING, XU, CHANGJIANG
Publication of US20130123212A1 publication Critical patent/US20130123212A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being

Definitions

  • the present invention belongs to medicine field, particularly relates to an anti-fatigue composition, formulation and use thereof.
  • the fatigue is defined that: the body's physiological processes can not maintain its function at a certain degree or the organs can not maintain its predetermined exercise intensity.
  • Fatigue is classified as central nervous system fatigue, nerve-muscle joint fatigue and peripheral fatigue of the limbs. Fatigue is a comprehensive physiological process involving many physiological and biochemical factors, and it's a normal physiological phenomenon inevitably occurring at a certain stage of the mental activity or physical activity of the body. It marks a temporary decline of the original work ability of the body, and may be an indication indicating the body develops to an injury status.
  • CFS Chronic Fatigue Syndrome
  • CFS is a group of syndrome, which takes long-term durable fatigue as prominent manifestation, accompanying with non-specific manifestations of low fever, headache, sore throat, muscle and joint pain, inattention, memory decline, sleep disorders, depression and the like, generally nothing abnormal is detected in physical examination and routine examination (Holmes G O, Kaplan J E, Gantz N M, et al. Chronic Fatigue Syndrome: A Working Case Definition. Ann Intern Med, 1988, 108(3): 387-389; Fukuda K, Straus S E, Hickie I, et al. The Chronic Fatigue Syndrome: A Comprehensive Approach to Definition and Study. Ann Intern Med, 1994, 121(12): 953-959).
  • CFS is more likely to happen in people at the age group of 20-50 years old, and more common in women.
  • CFS significantly affects work and living of a subject and gains great concern in the medical field.
  • Lycium chinense which is ripe fruit of a deciduous small shrub of Lycium plants in Solanaceae family, is a traditional Chinese herb medicine having effects of strengthening with tonics, replenishing vital essence, dispelling rheumatism, invigorating Yang, strengthening muscles and bones etc. It is recorded in an ancient Chinese medical book named Dietetic Materia Medica that, ripe fruits of Lycium chinense have the functions of “strengthening muscles to endure hard work, dispelling rheumatism, nourishing and benefiting muscles and bones, benefiting human body, and removing asthenic disease”.
  • Lycium chinense fruits the active ingredient of Lycium chinense fruits is lycium barbarum polysaccharide which has the functions of reducing the level of blood sugar and blood fat, improving immunity, antioxidation and anti-fatigue etc.
  • literatures reporting the anti-fatigue effect of Lycium chinense fruits as follows:
  • Protopanoxadiol is aglycon of ginsenoside diol set, including 20(S)-protopanoxadiol and 20(R)-protopanoxadiol, which are enantiomers to each other and are represented by the following formulas.
  • 20(S)-protopanoxadiol which does not occur naturally, is a metabolite of ginsenoside in the body.
  • Chinese Patent Application No. CN200610027507.1 discloses the anti-depression activity of 20(S)-protopanoxadiol;
  • Chinese Patent Application No. CN200610027508.6 discloses the anti-intestinal cancer activity of 20(S)-protopanoxadiol;
  • Chinese Patent Application No. CN200610131959.4 discloses novel use of ginsenoside Rh2 for anti-fatigue;
  • Chinese Patent Application No. CN200610017063.3 discloses anti-fatigue effect of a composition comprising ginseng, coffee and tea. The single use of 20(S)-protopanoxadiol for anti-fatigue has not been reported yet.
  • the object of the invention is to provide an anti-fatigue composition. Another object of the invention is to provide a formulation comprising the composition.
  • Still another object of the invention is to provide use of the composition.
  • the anti-fatigue composition according to the invention consists of 20(S)-protopanoxadiol and lycium barbarum polysaccharide.
  • the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-50 to 60-480.
  • the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-5 to 120-480.
  • the invention also provides a formulation comprising the above composition, wherein the formulation consists of the composition and pharmaceutically acceptable excipient, and the formulation may be in form of tablets, pills, capsules, granules or oral solution.
  • the pharmaceutically acceptable excipient is one or more selected from the group consisting of filler, disintegrating agent, adhesive, lubricant, diluent, sweetener, flavoring agent, coloring agent, emulsifier and suspending agent.
  • the filler is one or more selected from the group consisting of lactose, sucrose, dextrin, mannitol, sorbitol, microcrystalline cellulose and starch.
  • the disintegrating agent is selected from the group consisting of microcrystalline cellulose, starch, low substituted hydroxypropyl cellulose and crosslinked polyvinylpyrrolidone.
  • the adhesive is selected from the group consisting of polyvinylpyrrolidone, starch and ethanol.
  • the lubricant is selected from the group consisting of magnesium stearate, sodium lauryl sulfate, silica and talc.
  • the diluent is selected from the group consisting of water, ethanol, propylene glycol and glycerol.
  • the sweetener is one or more selected from the group consisting of glucose, fructose, sucrose, maltose, starch sugar and lactose.
  • the instant invention further provides use of the above composition and formulation thereof in the preparation of medicaments and healthcare products for anti-fatigue.
  • the fatigue may result from various causes.
  • the fatigue results from diseases.
  • the fatigue results from cancer or depression.
  • composition according to the invention which consists of 20(S)-protopanoxadiol and lycium barbarum polysaccharide has a synergistic effect in anti-fatigue.
  • 20(S)-protopanoxadiol provide by Shanghai innovative Research Center of Traditional Chinese Medicine, batch number: 20050606-1, purity: 94%; lycium barbarum polysaccharide: provided by Shanghai KangZhou Fungi Extract Co. Ltd., polysaccharide content ⁇ 30%.
  • mice are randomly divided into 19 groups by weight, 20 mice per each group; the detailed groups are as follows:
  • lycium barbarum polysaccharide 120 mg/kg
  • lycium barbarum polysaccharide 240 mg/kg
  • lycium barbarum polysaccharide 480 mg/kg
  • 0.2ml/10 g of drug is administrated by gavage every day; for normal control group, 0.2 ml/10 g of distilled water is administrated by gavage every day; once a day, 30 days in total.
  • the end of the tail of each mouse is loaded with copper wires corresponding to 6% of its body weight, then the mouse is put in a swimming box to swim, the time from start of swimming to death of the mouse is recorded, i.e. the mice burden swimming time; the water depth in the swimming box is 30cm or more, and water temperature is 23+1.0° C.
  • mice burden swimming test is conducted with drug dosages of 0.01-5 mg/kg of 20(S)-protopanoxadiol and 120-480 mg/kg of lycium barbarum polysaccharide, the results are shown in Table 1:
  • Table 1 show that: as compared with normal group, lycium barbarum polysaccharide can prolong the mice burden swimming time at different levels, the composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide in a weight ratio of 0.01-5 to 120-480 can prolong the mice burden swimming time at different levels (P ⁇ 0.01, P ⁇ 0.05); as compared with the effect of 20(S)-protopanoxadiol or lycium barbarum polysaccharide, the composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide in a weight ratio of 0.01-5 to 120-480 can also prolong the mice burden swimming time at different levels (P ⁇ 0.01, P ⁇ 0.05).
  • lactose 500 g is added to 4 g of 20(S)-protopanoxadiol and 2000 g of lycium barbarum polysaccharide, followed by mixing uniformly, taking 70% ethanol as adhesive, granulating, drying, and then adding 10 g of magnesium stearate and tabletting to obtain tablets.
  • lactose 200 g is added to 8 g of 20(S)-protopanoxadiol and 2000 g of lycium barbarum polysaccharide, followed by mixing uniformly, taking 70% ethanol as adhesive, granulating and filling in capsule to obtain the capsules.
  • Tween-80 100 g of Tween-80 is added to 16 g of 20(S)-protopanoxadiol and 2000 g of lycium barbarum polysaccharide, followed by grinding to form primary emulsion, adding water to a volume of 5000 ml to obtain the oral solution.
  • the anti-fatigue composition according to the invention consists of 20(S)-protopanoxadiol and lycium barbarum polysaccharide.
  • the experiments show that the composition can apparently prolong the swimming time of mice with weight loading, i.e. it exerts an obvious synergistic effect in anti-fatigue.
  • the composition according to the invention can be used in the preparation of anti-fatigue medicaments and healthcare products; it provides a novel method of relieving fatigue and possesses industrial applicability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. Experiments prove that the composition exhibits a significant anti-fatigue effect. In comparison with the effect attained by the single use of lycium barbarum polysaccharide or 20(S)-protopanoxadiol, the combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide exerts an obvious a clear synergistic effect.

Description

    TECHNICAL FIELD
  • The present invention belongs to medicine field, particularly relates to an anti-fatigue composition, formulation and use thereof.
    • BACKGROUND ART
  • At the fifth International Biochemistry of Exercise Congress in 1982, the fatigue is defined that: the body's physiological processes can not maintain its function at a certain degree or the organs can not maintain its predetermined exercise intensity.
  • Fatigue is classified as central nervous system fatigue, nerve-muscle joint fatigue and peripheral fatigue of the limbs. Fatigue is a comprehensive physiological process involving many physiological and biochemical factors, and it's a normal physiological phenomenon inevitably occurring at a certain stage of the mental activity or physical activity of the body. It marks a temporary decline of the original work ability of the body, and may be an indication indicating the body develops to an injury status.
  • At present people are paying more attention to the Chronic Fatigue Syndrome (CFS). CFS is a group of syndrome, which takes long-term durable fatigue as prominent manifestation, accompanying with non-specific manifestations of low fever, headache, sore throat, muscle and joint pain, inattention, memory decline, sleep disorders, depression and the like, generally nothing abnormal is detected in physical examination and routine examination (Holmes G O, Kaplan J E, Gantz N M, et al. Chronic Fatigue Syndrome: A Working Case Definition. Ann Intern Med, 1988, 108(3): 387-389; Fukuda K, Straus S E, Hickie I, et al. The Chronic Fatigue Syndrome: A Comprehensive Approach to Definition and Study. Ann Intern Med, 1994, 121(12): 953-959). CFS is more likely to happen in people at the age group of 20-50 years old, and more common in women. CFS significantly affects work and living of a subject and gains great concern in the medical field.
  • There are many causes which may lead to fatigue, such as working environment, diet habit and lifestyle, especially the diseases, which may bring to a subject mental stress, physical exertion, and lowered resistance in various functions of the body; as well as the physical exertion caused by drugs, which is easy to lead to fatigue. For example, the symptom of fatigue is normally seen in a cancer or mental patient who is subjected to a treatment.
  • Currently, the widely used methods of relieving fatigue adjust the body function by sleep and recuperation etc. On the other hand, the body function can be improved by recuperating with external materials. However, there is no anti-fatigue medicament or food with significant effect available in the current market.
  • Lycium chinense, which is ripe fruit of a deciduous small shrub of Lycium plants in Solanaceae family, is a traditional Chinese herb medicine having effects of strengthening with tonics, replenishing vital essence, dispelling rheumatism, invigorating Yang, strengthening muscles and bones etc. It is recorded in an ancient Chinese medical book named Dietetic Materia Medica that, ripe fruits of Lycium chinense have the functions of “strengthening muscles to endure hard work, dispelling rheumatism, nourishing and benefiting muscles and bones, benefiting human body, and removing asthenic disease”. Research of modern pharmacology proves that, the active ingredient of Lycium chinense fruits is lycium barbarum polysaccharide which has the functions of reducing the level of blood sugar and blood fat, improving immunity, antioxidation and anti-fatigue etc. At present, there are literatures reporting the anti-fatigue effect of Lycium chinense fruits as follows:
  • LUO Qiong et al. reports the influence of lycium barbarum polysaccharide on the anti-fatigue effect of mice, experiments show that lycium barbarum polysaccharide is the main ingredient for anti-fatigue effect of Lycium chinense fruits (LUO Qiong, YAN Jun and ZHANG Shenghua. Influence of Lycium Barbarum Polysaccharide on the Anti-fatigue Effect for Mice. Journal of Hubei Medical University, 1999, No. 4); WANG Yanwu et al. reports that lycium barbarum polysaccharide has anti-fatigue effect (WANG Yanwu, FU Weizhong, TAN Zongyan et al. Experimental Research on Anti-fatigue Effect of Lycium Barbarum Polysaccharide. China Tropical Medicine, 2006, No. 8, August 2006,(6):8); PAN Jingyi et al. reports that Lycium chinense fruits has functions of anti-fatigue, improving exercise tolerance and immunity for mice (Experimental Research on Anti-fatigue and Improving Immunity Effects of Lycium chinense Fruits, Shanghai Journal of Preventive Medicine, 2003, Vol. 15, No. 8).
  • Protopanoxadiol is aglycon of ginsenoside diol set, including 20(S)-protopanoxadiol and 20(R)-protopanoxadiol, which are enantiomers to each other and are represented by the following formulas.
  • Figure US20130123212A1-20130516-C00001
  • 20(S)-protopanoxadiol, which does not occur naturally, is a metabolite of ginsenoside in the body. Chinese Patent Application No. CN200610027507.1 discloses the anti-depression activity of 20(S)-protopanoxadiol; Chinese Patent Application No. CN200610027508.6 discloses the anti-intestinal cancer activity of 20(S)-protopanoxadiol; Chinese Patent Application No. CN200610131959.4 discloses novel use of ginsenoside Rh2 for anti-fatigue; Chinese Patent Application No. CN200610017063.3 discloses anti-fatigue effect of a composition comprising ginseng, coffee and tea. The single use of 20(S)-protopanoxadiol for anti-fatigue has not been reported yet.
  • Although lycium barbarum polysaccharide has a certain anti-fatigue effect, such effect needs to be improved. Until now, there is no patent or literature reporting using 20(S)-protopanoxadiol and lycium barbarum polysaccharide for anti-fatigue.
    • CONTENTS OF THE INVENTION
  • The object of the invention is to provide an anti-fatigue composition. Another object of the invention is to provide a formulation comprising the composition.
  • Still another object of the invention is to provide use of the composition.
  • The anti-fatigue composition according to the invention consists of 20(S)-protopanoxadiol and lycium barbarum polysaccharide.
  • In the composition, the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-50 to 60-480.
  • Preferably in the composition, the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-5 to 120-480.
  • The invention also provides a formulation comprising the above composition, wherein the formulation consists of the composition and pharmaceutically acceptable excipient, and the formulation may be in form of tablets, pills, capsules, granules or oral solution.
  • The pharmaceutically acceptable excipient is one or more selected from the group consisting of filler, disintegrating agent, adhesive, lubricant, diluent, sweetener, flavoring agent, coloring agent, emulsifier and suspending agent.
  • The filler is one or more selected from the group consisting of lactose, sucrose, dextrin, mannitol, sorbitol, microcrystalline cellulose and starch.
  • The disintegrating agent is selected from the group consisting of microcrystalline cellulose, starch, low substituted hydroxypropyl cellulose and crosslinked polyvinylpyrrolidone.
  • The adhesive is selected from the group consisting of polyvinylpyrrolidone, starch and ethanol.
  • The lubricant is selected from the group consisting of magnesium stearate, sodium lauryl sulfate, silica and talc.
  • The diluent is selected from the group consisting of water, ethanol, propylene glycol and glycerol.
  • The sweetener is one or more selected from the group consisting of glucose, fructose, sucrose, maltose, starch sugar and lactose.
  • The instant invention further provides use of the above composition and formulation thereof in the preparation of medicaments and healthcare products for anti-fatigue.
  • The fatigue may result from various causes.
  • Preferably the fatigue results from diseases.
  • More preferably the fatigue results from cancer or depression.
  • Experiments show that the composition according to the invention which consists of 20(S)-protopanoxadiol and lycium barbarum polysaccharide has a synergistic effect in anti-fatigue.
    • SPECIFIC MODE FOR CARRYING OUT THE INVENTION
  • The following Examples are intended to further illustrate the present invention without limiting its scope.
    • Experimental Example 1 Effect of Composition Consisting of 20(S)-protopanoxadiol and Lycium barbarum Polysaccharide on Mice Burden Swimming Time
  • According to the Technical Standards for Testing & Assessment of Health Food issued by the Ministry of Health, P. R. China, function and biochemistry indexes assessment of the mixture of 20(S)-protopanoxadiol and lycium barbarum polysaccharide on the function of relieving physical fatigue is conducted; the detailed method is given as follows:
  • 1. Experimental animals: ICR mice, male, 18-22g, provided by Shanghai Slack laboratory animal Co. Ltd., license number: SCXK (Shanghai) 2007-0005;
  • 2. Experimental drugs:
  • 20(S)-protopanoxadiol: provide by Shanghai Innovative Research Center of Traditional Chinese Medicine, batch number: 20050606-1, purity: 94%; lycium barbarum polysaccharide: provided by Shanghai KangZhou Fungi Extract Co. Ltd., polysaccharide content≧30%.
  • To 20(S)-protopanoxadiol is added a small amount of 0.3% CMC-Na, followed by grinding to form a suspension and diluting with CMC-Na to a desired concentration. Then lycium barbarum polysaccharide is added to the 20(S)-protopanoxadiol suspension to form a composition with a certain concentration.
  • 3. Experimental groups: the mice are randomly divided into 19 groups by weight, 20 mice per each group; the detailed groups are as follows:
  • normal (solvent) control
  • 20(S)-protopanoxadiol: 0.01 mg/kg
  • 20(S)-protopanoxadiol: 0.5 mg/kg
  • 20(S)-protopanoxadiol: 1 mg/kg
  • lycium barbarum polysaccharide: 120 mg/kg
  • lycium barbarum polysaccharide: 240 mg/kg
  • lycium barbarum polysaccharide: 480 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 0.01 mg/kg+120 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 0.01 mg/kg+240 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 0.01 mg/kg+480 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 0.5 mg/kg+120 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 0.5 mg/kg+240 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 0.5 mg/kg+480 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 1 mg/kg+120 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 1 mg/kg+240 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 1 mg/kg+480 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 5 mg/kg+120 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 5 mg/kg+240 mg/kg
  • 20(S)-protopanoxadiol+lycium barbarum polysaccharide: 5 mg/kg+480 mg/kg
  • 4. Experimental method:
  • 0.2ml/10 g of drug is administrated by gavage every day; for normal control group, 0.2 ml/10 g of distilled water is administrated by gavage every day; once a day, 30 days in total.
  • 30 minutes after the last time of administrating drug, the end of the tail of each mouse is loaded with copper wires corresponding to 6% of its body weight, then the mouse is put in a swimming box to swim, the time from start of swimming to death of the mouse is recorded, i.e. the mice burden swimming time; the water depth in the swimming box is 30cm or more, and water temperature is 23+1.0° C.
  • 5. Statistical data processing: t-test is conducted to calculate P value, Jin Zhengjun formula is used to conduct combined medication analysis.
  • 6. Experimental results:
  • Mice burden swimming test is conducted with drug dosages of 0.01-5 mg/kg of 20(S)-protopanoxadiol and 120-480 mg/kg of lycium barbarum polysaccharide, the results are shown in Table 1:
  • TABLE 1
    Effect of 20(S)-protopanoxadiol and lycium barbarum polysaccharide on
    mice burden swimming time ( x ± S)
    Animal Change rate
    Dosage Animal weight Swimming of swimming
    Groups (mg/kg) number start/finish (g) time (s) time (%)
    normal control group solvent 20 21.7/39.3 620 ± 285 
    20(S)-protopanoxadiol 0.01 20 21.6/39.2 640 ± 275  1.5
    20(S)-protopanoxadiol 0.5 20 21.8/38.8 660 ± 268  1.9
    20(S)-protopanoxadiol 1 20 21.7/38.7 658 ± 296  2.2
    20(S)-protopanoxadiol 5 20 21.8/38.9 640 ± 286  1.5
    lycium barbarum 120 20 21.7/39.5 783 ± 189** 26.4
    polysaccharide
    lycium barbarum 240 20 21.8/39.7 794 ± 385** 28.1
    polysaccharide
    lycium barbarum 480 20 21.8/38.8 766 ± 282*  23.5
    polysaccharide
    20(S)-protopanoxadiol + lycium 0.01 + 120  20 21.7/39.5 798 ± 235** 28
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 0.01 + 240  20 21.8/39.2 843 ± 283** 40
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 0.01 + 480  20 21.9/38.8 865 ± 298** 42.6
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  0.5 + 120  20 21.8/39.3 853 ± 229** 35.5
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  0.5 + 240  20 21.8/39.1 898 ± 322** 44.8
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  0.5 + 480  20 21.8/38.7 923 ± 224** 48.9
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  1 + 120 20 21.8/39.4 842 ± 252** 35.78
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  1 + 240 20 21.9/39.1 993 ± 289** 60.2
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  1 + 480 20 21.8/38.3 1063 ± 342**  71.4
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  5 + 120 20 21.7/39.2 875 ± 279** 36.42
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  5 + 240 20 21.9/38.8 1069 ± 243**  62.8
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  5 + 480 20 21.8/39.0 1185 ± 242**  75.1
    barbarum polysaccharide
    Note:
    compared with normal control group,
    *P < 0.05,
    **P < 0.01
  • The results in Table 1 show that: as compared with normal group, lycium barbarum polysaccharide can prolong the mice burden swimming time at different levels, the composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide in a weight ratio of 0.01-5 to 120-480 can prolong the mice burden swimming time at different levels (P<0.01, P<0.05); as compared with the effect of 20(S)-protopanoxadiol or lycium barbarum polysaccharide, the composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide in a weight ratio of 0.01-5 to 120-480 can also prolong the mice burden swimming time at different levels (P<0.01, P<0.05).
  • Conclusion: combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide exerts an obvious synergistic effect.
    • Experimental Example 2 Effects of the Combined Dosage of 20(S)-protopanoxadiol and Lycium barbarum Polysaccharide on Mice Burden Swimming Time
  • Other than the combined dosage of Experimental example 1, the range of combined dosage is enlarged to conduct multi-batch experiments. The experimental animals, drugs and method are the same as those of Experimental example 1, and the final results are shown in Table 2:
  • TABLE 2
    Effect of 20(S)-protopanoxadiol and lycium barbarum polysaccharide on
    mice burden swimming time
    Swimming time
    Dosage change rate
    Groups (mg/kg) (%)
    normal control group solvent 0 
    20(S)-protopanoxadiol 0.01 1.5
    20(S)-protopanoxadiol 0.5 1.9
    20(S)-protopanoxadiol 1 2.2
    20(S)-protopanoxadiol 3 1.6
    20(S)-protopanoxadiol 6.25 1.4
    20(S)-protopanoxadiol 12.5 3.4
    20(S)-protopanoxadiol 25 6.9
    20(S)-protopanoxadiol 50 12.4*
    lycium barbarum polysaccharide 10 7.5
    lycium barbarum polysaccharide 30 8.1
    lycium barbarum polysaccharide 60 10.5 
    lycium barbarum polysaccharide 120  26.4**
    lycium barbarum polysaccharide 240  28.1**
    lycium barbarum polysaccharide 480 23.5*
    20(S)-protopanoxadiol + lycium 0.01 + 60   21.3*
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 0.01 + 120    28**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 0.01 + 240    40**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 0.01 + 480  42.6**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 0.5 + 60  25.5**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  0.5 + 120  35.5**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  0.5 + 240  44.8**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  0.5 + 480  48.9**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  1 + 60 22.6* 
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  1 + 120 35.78** 
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  1 + 240 60.2**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  1 + 480 71.4**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  3 + 60 22.8* 
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  3 + 120 36.8**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  3 + 240 38.7**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 6.25 + 60   17.6* 
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 6.25 + 120  22.5* 
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 6.25 + 240  32.9**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 12.5 + 120  26.6**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 25 + 60 38.1**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  25 + 120 41.7**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  25 + 240 50.1**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  25 + 480 32.9**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium 50 + 60 41.9**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  50 + 120 42.8**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  50 + 240 48.1**
    barbarum polysaccharide
    20(S)-protopanoxadiol + lycium  50 + 480 55.5**
    barbarum polysaccharide
    Note:
    compared with normal control group,
    *P < 0.05,
    **P < 0.01
  • The results in Table 2 show that: as compared with normal control group, single use of 20(S)-protopanoxadiol has no significant effect on mice swimming time (P>0.05), use of 120-480 mg/kg of lycium barbarum polysaccharide alone can prolong mice swimming time at different levels (P<0.05, P<0.01), the composition of 20(S)-protopanoxadiol and lycium barbarum polysaccharide in a weight ratio of 0.01-50 to 60-480 can apparently prolong mice burden swimming time (P<0.01 or P<0.05); as compared with the effect of use of 20(S)-protopanoxadiol or lycium barbarum polysaccharide alone, the effect of combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide on mice burden swimming time is bigger than the sum of the effects of single use of the two, that is to say, although 20(S)-protopanoxadiol has no effect on mice burden swimming endurance, combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide exerts apparent and unexpected synergistic effect.
  • Conclusion: combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide exerts apparent synergistic effect.
    • Example 1 Tablets of the Anti-Fatigue Composition
  • 500 g of lactose is added to 4 g of 20(S)-protopanoxadiol and 2000 g of lycium barbarum polysaccharide, followed by mixing uniformly, taking 70% ethanol as adhesive, granulating, drying, and then adding 10 g of magnesium stearate and tabletting to obtain tablets.
    • Example 2 Capsules of the Anti-Fatigue Composition
  • 200 g of lactose is added to 8 g of 20(S)-protopanoxadiol and 2000 g of lycium barbarum polysaccharide, followed by mixing uniformly, taking 70% ethanol as adhesive, granulating and filling in capsule to obtain the capsules.
    • Example 3 Oral Solution of the Anti-Fatigue Composition
  • 100 g of Tween-80 is added to 16 g of 20(S)-protopanoxadiol and 2000 g of lycium barbarum polysaccharide, followed by grinding to form primary emulsion, adding water to a volume of 5000 ml to obtain the oral solution.
    • INDUSTRIAL APPLICABILITY
  • The anti-fatigue composition according to the invention consists of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. The experiments show that the composition can apparently prolong the swimming time of mice with weight loading, i.e. it exerts an obvious synergistic effect in anti-fatigue. In comparison with the effect attained by the single use oflycium barbarum polysaccharide or 20(S)-protopanoxadiol, the combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide exerts an obvious synergistic effect. The composition according to the invention can be used in the preparation of anti-fatigue medicaments and healthcare products; it provides a novel method of relieving fatigue and possesses industrial applicability.

Claims (14)

1. An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide.
2. The composition according to claim 1, wherein the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 1:50 to 1:1000.
3. A formulation comprising the composition according to claim 1, wherein the formulation consists of 20(S)-protopanoxadiol, lycium barbarum polysaccharide and pharmaceutically acceptable excipients.
4. The formulation according to claim 3, wherein the formulation is in form of tablets, pills, capsules, granules or oral solution.
5. A method for relieving fatigue, comprising administering the composition of claim 1 to a subject.
6. A method for relieving fatigue, comprising administering the formulation of claim 3 to a subject.
7. The method of claim 5, wherein the fatigue results from various causes.
8. The method of claim 7, wherein the fatigue results from diseases.
9. The method of claim 8, wherein the fatigue results from cancer or depression.
10. (canceled)
11. The composition according to claim 1, wherein the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-50 to 60-480.
12. The composition according to claim 11, wherein the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-5 to 120-480.
13. The formulation according to claim 3, wherein the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-50 to 60-480.
14. The formulation according to claim 13, wherein the weight ratio of the 20(S)-protopanoxadiol and lycium barbarum polysaccharide is 0.01-5 to 120-480.
US13/812,485 2010-07-27 2011-07-27 Anti-fatigue composition, formulation and use thereof Abandoned US20130123212A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2010102379550A CN101890040B (en) 2010-07-27 2010-07-27 Composition with anti-fatigue effect and application thereof
CN201010237955.0 2010-07-27
PCT/CN2011/001233 WO2012013020A1 (en) 2010-07-27 2011-07-27 Anti-fatigue composition, formulation and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001233 A-371-Of-International WO2012013020A1 (en) 2010-07-27 2011-07-27 Anti-fatigue composition, formulation and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/535,257 Division US9603866B2 (en) 2010-07-27 2014-11-06 Anti-fatigue composition, formulation and use thereof

Publications (1)

Publication Number Publication Date
US20130123212A1 true US20130123212A1 (en) 2013-05-16

Family

ID=43099498

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/812,485 Abandoned US20130123212A1 (en) 2010-07-27 2011-07-27 Anti-fatigue composition, formulation and use thereof
US14/535,257 Expired - Fee Related US9603866B2 (en) 2010-07-27 2014-11-06 Anti-fatigue composition, formulation and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/535,257 Expired - Fee Related US9603866B2 (en) 2010-07-27 2014-11-06 Anti-fatigue composition, formulation and use thereof

Country Status (7)

Country Link
US (2) US20130123212A1 (en)
EP (1) EP2599490B1 (en)
JP (1) JP5797268B2 (en)
KR (1) KR101735151B1 (en)
CN (1) CN101890040B (en)
RU (1) RU2559784C2 (en)
WO (1) WO2012013020A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112451655A (en) * 2020-12-10 2021-03-09 中国科学院兰州化学物理研究所 Anti-fatigue composition and application thereof
CN113041225A (en) * 2021-03-26 2021-06-29 齐晓慧 Sugar-containing Mongolian medicine powder formula granule and preparation method thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890040B (en) 2010-07-27 2011-12-21 上海中药创新研究中心 Composition with anti-fatigue effect and application thereof
CN102697047B (en) * 2012-06-11 2013-11-06 宁夏红中宁枸杞制品有限公司 Method for preparing oral liquid of Chinese wolfberry
CN109105702A (en) * 2018-08-30 2019-01-01 泓博元生命科技（深圳）有限公司 A kind of preparation method of composition containing NADH, application and energy extender
CN109170907A (en) * 2018-08-30 2019-01-11 泓博元生命科技（深圳）有限公司 A kind of preparation method of composition containing NMN, application and sports drink
CN109997946A (en) * 2019-02-20 2019-07-12 山东佰诺生物科技有限公司 A kind of compound pressed candy and preparation method thereof
KR101988959B1 (en) 2019-05-13 2019-06-14 주식회사 한미양행 Stress relieving or anti-fatigue composition containing enzymatic treatment white grub
CN111529539A (en) * 2020-04-29 2020-08-14 海南亚洲制药股份有限公司 Application of protopanoxadiol in preparing medicine
CN112656870B (en) * 2021-01-20 2022-07-05 森隆药业有限公司 Anti-fatigue traditional Chinese medicine composition and preparation method and application thereof
KR20220151393A (en) 2021-05-06 2022-11-15 도영복 Health functional tea composition for stress relief containing ginseng
CN113633657B (en) * 2021-05-08 2024-03-01 中国人民解放军海军军医大学 Pharmaceutical composition for improving body anti-fatigue, hypoxia-resistant, heat-resistant and cold-resistant capacities and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3298214B2 (en) * 1992-03-27 2002-07-02 大正製薬株式会社 Liquid for internal use
JP2002275086A (en) * 2001-03-15 2002-09-25 Fancl Corp Composition for improving frail constitution
RU2188627C1 (en) * 2001-04-26 2002-09-10 ООО НПО "Фитофарм" Method for preventing oral cavity diseases
RU2004137801A (en) * 2002-06-11 2005-10-10 Панагин Фармацетикалс Инк. (Ca) COMPOSITION FOR CANCER THERAPY BY SAPONINES OR SAPOGENINS
CN100374135C (en) * 2004-10-13 2008-03-12 王炤 Ginseng pills of sea dog
CN1895257A (en) * 2006-06-09 2007-01-17 上海中药创新研究中心 Use of 20(S)-protopanoxadiol in preparation of anti-bowelcancer medicine
CN101086459A (en) 2006-06-09 2007-12-12 中国第二十冶金建设公司 Plate blank weighing machine lifting cylinder changing method
CN100438876C (en) * 2006-06-09 2008-12-03 上海中药创新研究中心 Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine
CN100405921C (en) 2006-08-02 2008-07-30 吉林华康药业股份有限公司 An anti-fatigue health food
CN101161246B (en) 2006-10-12 2012-03-21 海南亚洲制药有限公司 New purpose of ginsenoside Rh2
US20080124416A1 (en) * 2006-11-28 2008-05-29 Renaissance Herbs, Inc. Therapeutic composition from goji (lycium barbarum l.), methods of making and using
CA2715704A1 (en) * 2008-02-19 2009-08-27 Sung Sick Woo Leaves extract of panax sp., a process of making the same and uses thereof
CN101612159B (en) * 2008-06-23 2011-08-31 上海药谷药业有限公司 Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament
KR20100050192A (en) * 2008-11-05 2010-05-13 성신여자대학교 산학협력단 The bio-functional ginseng extracts controlled by the ratio of protopanaxadiols and protopanaxtriols
CN101628071A (en) * 2009-08-25 2010-01-20 红桃开集团股份有限公司 Medicament composition for strengthening kidney and tonifying Yang
CN101756090B (en) * 2009-12-18 2012-08-01 中国人民武装警察部队后勤学院 Physical power recovery agent and applications thereof
CN101890040B (en) * 2010-07-27 2011-12-21 上海中药创新研究中心 Composition with anti-fatigue effect and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Li, X. M., Ma, Y. L., & Liu, X. J. (2007). Effect of the Lycium barbarum polysaccharides on age-related oxidative stress in aged mice. Journal of ethnopharmacology, 111(3), 504-511. *
Luo et al. Lycium barbarum Polysaccharides Induce Apoptosis in Human Prostate Cancer Cells and Inhibits Prostate Cancer Growth in a Xenograft Mouse Model of Human Prostate Cancer. J Med Food 12 (4) 2009, 695-703 *
Wang et al. Antiprostate cancer effects of 25-OCH3-PPD. British Journal of Cancer (2008) 98(4), 792 - 802 *
Xu et al., CN 101890040 A, 11-2010, machine translation, Retreived on 6/12/2013 from http://worldwide.espacenet.com *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112451655A (en) * 2020-12-10 2021-03-09 中国科学院兰州化学物理研究所 Anti-fatigue composition and application thereof
CN113041225A (en) * 2021-03-26 2021-06-29 齐晓慧 Sugar-containing Mongolian medicine powder formula granule and preparation method thereof

Also Published As

Publication number Publication date
EP2599490A4 (en) 2014-01-08
WO2012013020A8 (en) 2013-02-21
CN101890040B (en) 2011-12-21
KR101735151B1 (en) 2017-05-24
RU2559784C2 (en) 2015-08-10
EP2599490B1 (en) 2016-05-04
JP2013532666A (en) 2013-08-19
WO2012013020A1 (en) 2012-02-02
RU2013106172A (en) 2014-09-10
EP2599490A1 (en) 2013-06-05
US20150065452A1 (en) 2015-03-05
KR20130131303A (en) 2013-12-03
JP5797268B2 (en) 2015-10-21
HK1182934A1 (en) 2013-12-13
CN101890040A (en) 2010-11-24
US9603866B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
US9603866B2 (en) Anti-fatigue composition, formulation and use thereof
CN109674958B (en) Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof
JP6446552B2 (en) Compositions used for weight and body fat reduction and their pharmaceuticals and uses
WO2012027882A1 (en) Pharmaceutical composition for treating insomnia and preparation method thereof
TWI678211B (en) Uses of cistanche tubulosa extract and isoacteoside in protecting muscles
CN110960624A (en) Anti-fatigue composition and preparation method thereof
TW202200129A (en) Nicotinamide adenine dinucleotide (NAD) concentration increasing agent
CN107998370B (en) Composition capable of enhancing body motion ability and relieving motion fatigue
WO2016167855A1 (en) Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia
US11311587B2 (en) Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue
KR20140030360A (en) A pharmaceutical comprising the extract of red ginseng for preventing and treating influenza like illness
CN103830584B (en) Medicine for the treatment of Vertebral Artery Ischemic Disease and preparation method thereof
CN1141125C (en) Chinese medicine composition with hypoglycemic effect
HK1182934B (en) Anti-fatigue composition, formulation and use thereof
US20220193173A1 (en) Traditional Chinese Medicine Composition for Loosening Bowel to Relieve Constipation, Preparation Method and Application Thereof
CN104095868B (en) A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance
CN110420209B (en) Pharmaceutical composition for treating diabetic peripheral neuralgia and application thereof
EP3466414B1 (en) Use of nootkatone
JP2024017059A (en) Cold symptom suppressant
KR20250097672A (en) Composition for antifatigue or enhancing exercise performance comprising Lambertianic acid as effective component
CN116650511A (en) Low-toxicity high-efficiency composition for preventing and treating depression
CN1278704C (en) Health products for reducing blood sugar and blood fat in assistance
CN105770220A (en) Pharmaceutical composition containing losartan and capable of treating hypertension and preparation method thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHANG HAI INNOVATIVE RESEARCH CENTER OF TRADITIONA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:XU, CHANGJIANG;JIA, WEIGUO;YU, CHUNYING;AND OTHERS;SIGNING DATES FROM 20130124 TO 20130125;REEL/FRAME:029736/0069

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION